Back to top
more

Doximity (DOCS)

(Real Time Quote from BATS)

$36.30 USD

36.30
697,190

+0.70 (1.97%)

Updated Aug 12, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix

by Zacks Equity Research

Medpace, Doximity and Biodesix have been highlighted in this Industry Outlook article.

Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?

by Zacks Equity Research

Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy as Industry Trends Improve

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend.

ICLR or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ICLR vs. DOCS: Which Stock Is the Better Value Option?

Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Doximity (DOCS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.

MD or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. DOCS: Which Stock Is the Better Value Option?

Implied Volatility Surging for Doximity (DOCS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Doximity (DOCS) stock based on the movements in the options market lately.

Here's What Key Metrics Tell Us About Doximity (DOCS) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 26.67% and 1.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

DocGo Inc. (DCGO) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Avantor, Inc. (AVTR) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -3.45% and 3.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 9.09% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?

Here's Why You Should Hold Centene (CNC) Stock for Now

by Zacks Equity Research

Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.

BLCO or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BLCO vs. DOCS: Which Stock Is the Better Value Option?

Doximity (DOCS) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Doximity (DOCS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Nutex Health Inc. (NUTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nutex Health Inc. (NUTX) delivered earnings and revenue surprises of 50% and 1.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agilon Health (AGL) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of 33.33% and 5.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?